Overview
Lobbying Costs
100,000€ - 199,999€
Financial year: Jan 2023 - Dec 2023
Lobbyists (Full time equivalent)
0.75 Fte (2)
Lobbyists with EP accreditation
0
High-level Commission meetings
1
Lobbying Costs over the years
-
Info
Medtech & Pharma Platform Association (MPP)
EU Transparency Register
234427831877-10 First registered on 25 Jun 2018
Goals / Remit
The Medtech & Pharma Platform Association (MPP) is a European cross-sectoral not-for-profit industry Association focusing on combined products, i.e. products that combine drugs, devices, diagnostics and/or digital elements to fulfill a medical purpose. Members are medtech, diagnostic, pharma and tech companies as well as organizations dedicated to enhancing synergies between the sectors. Current and future innovative healthcare solutions increasingly rely on combined products, integrating various combinations of pharma, medtech and digital technologies. MPP offers expertise and seeks dialogue with relevant stakeholders to collaborate on a proportionate regulatory framework for combined products, with a view to facilitate patient access to innovation, foster European competitiveness and enhance the safety of health data.
Main EU files targeted
The Medtech & Pharma Platform Association was founded in 2017 and started its activities in 2018.
The Medtech & Pharma Platform monitors EU legislative, policy and regulatory developments relating to combined products.
Specifically, the Medtech & Pharma Platform follows:
• Medical Devices Regulation EU 2017/745 & In vitro Diagnostics Regulation EU 2017/746
and their implementing and delegated acts as well as any related guidance document
• Medicinal Products Directive EU 2001/83
• EU Pharmaceutical Strategy
• Revision of the EU basic pharmaceutical legislation
• Advanced Therapy Medicinal Product Regulation EU 1394/2007
• Regulation on Health Technology Assessment EU 2021/2282
• EMA Quality Innovation Group
• Regulation on standards of quality and safety for substances of human origin
• Regulation on the classification, labelling and packaging of chemicals
• General Data Protection Regulation EU 2016/679
• Clinical Trials Regulation EU 536/2014
• Accelerating Clinical Trials in the EU (ACT EU)
• Implementation of the Union list of critical medicines
• Critical Raw Materials Act
• Policy initiatives, projects, events and publications from DG SANTE, DG GROW, DG CONNECT, DG RESEARCH & INNOVATION
• European Health and Digital Executive Agency (HaDEA)
• Health emergency preparedness and response authority (HERA)
• European Industrial strategy
• European Digital Strategy and Artificial Intelligence
• Horizon Europe
• European Health Data Space
• Data Governance Act and Data Act
• Proposal for Regulation on Artificial Intelligence
• EU AI Observatory
• EU Beating Cancer Plan
• European Health Union
• Intellectual property action plan
• Regulation of Ethylene Oxide
• Regulation of Per- and polyfluoroalkyl substances (PFAS)
• EMA draft reflection paper on AI and ML
• EMA “COMBINE” Project
• Institutional agreement Switzerland-EUAddress
Head Office
Medtech & Pharma Platform Association c/o SFL Regulatory Affairs & Scientific Communication GmbH Aeschenvorstadt 52
Basel 4051
SWITZERLANDEU Office
Medtech & Pharma Platform Association c/o SFL Regulatory Affairs & Scientific Communication GmbH Aeschenvorstadt 52
Basel 4051
SWITZERLANDWebsite
-
People
Total lobbyists declared
2
Employment time Lobbyists 50% 1 25% 1 Lobbyists (Full time equivalent)
0.75
Lobbyists with EP accreditation
No lobbyists with EP accreditations
Complementary Information
Within the cluster of 25% working time, two people work 12.5% making a joint total of 25%. In total, 3 people are involved.
Person in charge of EU relations
Data not provided by Register Secretariat due to GDPR
Person with legal responsibility
Data not provided by Register Secretariat due to GDPR
-
Categories
Category
Trade and business associations
-
Networking
Affiliation
N/A
Member organisations
None declared
-
Financial Data
Interests represented
Promotes their own interests or the collective interests of their members
Closed financial year
Jan 2023 - Dec 2023
Lobbying costs for closed financial year
100,000€ - 199,999€
Major contributions in closed year
None declared
Intermediaries for closed year
Name Amount sfl regulatory affairs & scientific communication gmbh 100,000€ - 199,999€ Intermediaries for current year
Name sfl regulatory affairs & scientific communication gmbh Closed year Costs
100,000€ - 199,999€
Other financial info
MPP is funded by membership contributions.
-
EU Structures
Groups (European Commission)
none
Groups (European Parliament)
N/A
Communication activities
Stakeholder engagement, projects:
The MPP engages with relevant stakeholders on a European level, offers expertise and seeks dialogue to collaborate on a proportionate regulatory framework for combined products.
MPP has three active working groups:
• Working Group on Combined Products, focusing on co-packaged and non co-packaged drug-device-combinations and single integral combination products,
• Working Group on Connected Combined Products, focusing on connected combined products including drugs, medical devices, in-vitro diagnostics, digital applications,
• Working Group on in vitro diagnostics and companion diagnostics.
Publications:
• Position paper on the Interface between the EU MDR, IVDR and CTR: Challenges in conducting clinical trials involving medicinal products with medical devices or IVDs
• Paper on regulatory pathways for connected combined products, examining the challenges associated with regulatory pathways in the EU for a subset of connected combined products consisting of a medicinal product used with a delivery device with wireless connectivity to a standalone software, September 2023
• T.C. Kühler and al., Development and Regulation of Connected Combined Products: Reflections From the Medtech & Pharma Platform Association, Clinical Therapeutics, Volume 44, ISSUE 5, P768-782, 1 May 2022
• MPP Best Practice Guide for clinical trials with integral Drug-Device Combination Products including change control and usability studies, December 2020
• Position paper on the legislative framework for Connected Combined Products, October 2020
• Reflection paper on regulatory uncertainties for co-packaged and cross-labelled drug-device combinations under the new Medical Device Regulation, December 2019
• White Paper on EU regulatory and policy framework for combined products, October 2018
Events:
• MPP annual conference: The annual MPP conference is the leading event in the sector of products and solutions that combine pharma, medtech, diagnostic and digital components. The event is dedicated to enhancing synergies between these sectors. The conference provides a forum to exchange knowledge, identify new challenges and opportunities, initiate collaborations and propose improvements to regulatory frameworks and policy, toward the goal of improving patient access to innovative combined products
• MPP webinars: The MPP Association offers webinars providing comprehensive and up-to-date insights on the latest regulatory and legislative developments related to combined products, medicinal products, medical devices, and in-vitro diagnostics.Other activities
None declared
Meetings
Meetings
1 meetings found. Download meetings
The list below only covers meetings held since November 2014 with commissioners, their cabinet members or directors-general at the European Commission; other lobby meetings with lower-level staff may have taken place, but the European Commission doesn't proactively publish information about these meetings. For more information about which commissioner is responsible for which portfolio, check out this link: https://commissioners.ec.europa.eu/index_en All information below comes from European Commission web pages.
1 July 2024: We have noted that some meetings are appearing in duplicate, ie. some meetings seem to be listed twice. This seems to be because the Commission changes some element of a meeting data after the meeting has first been listed, which causes LobbyFacts to register it as a new meeting. We are investigating further.
-
Date 15 Jun 2018 Location Brussels, Berl Subject HTA Cabinet Cabinet of Commissioner Vytenis Andriukaitis Portfolio Health & Food Safety Attending - Annika Nowak (Cabinet member)
- Vytenis Andriukaitis (Commissioner)
Other Lobbyists